TABLE 3.
Results of the analysis of the secondary outcomes (efficacy and safety) in the observational study compared with the ROCKET AF trial
| Outcome | Observational study | ROCKET AF trial | ||
|---|---|---|---|---|
| Riivaroxaban | Warfarin | Rivaroxaban | Warfarin | |
| Composite endpoint of stroke, systemic embolism, or vascular death | ||||
| Number of events | 274 | 3123 | 346 | 410 |
| Event rate: number/100 person‐years | 5.03 | 4.76 | 3.11 | 3.63 |
| Hazard ratio (95% CI) | 1.18 (1.03‐1.34) | Reference | 0.86 (0.74‐0.99) | Reference |
| Major bleeding | ||||
| Number of events | 294 | 2849 | 395 | 386 |
| Event rate: number/100 person‐years | 5.68 | 4.72 | 3.60 | 3.40 |
| Hazard ratio (95% CI) | 1.07 (0.95‐1.21) | Reference | 1.04 (0.90‐1.20) | Reference |